These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26952004)

  • 21. The role of stochastic gene switching in determining the pharmacodynamics of certain drugs: basic mechanisms.
    Puszynski K; Gandolfi A; d'Onofrio A
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):395-410. PubMed ID: 27352096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simple designs and model-free tests for synergy.
    Laska EM; Meisner M; Siegel C
    Biometrics; 1994 Sep; 50(3):834-41. PubMed ID: 7981403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Model building in pharmacokinetics/Part V: Simulation of blood level curves following repetitive dosing and their experimental verification (author's transl)].
    Hammer R; Bozler G; Heinzel G; Koss FW
    Arzneimittelforschung; 1977; 27(4a):928-31. PubMed ID: 577860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-incidence modeling: consequences of linking quantal measures of response to depletion of critical tissue targets.
    Andersen ME; Lutz RW; Liao KH; Lutz WK
    Toxicol Sci; 2006 Jan; 89(1):331-7. PubMed ID: 16237194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical properties of the NOAEL.
    Leisenring W; Ryan L
    Regul Toxicol Pharmacol; 1992 Apr; 15(2 Pt 1):161-71. PubMed ID: 1626067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The estimation of relative potency from two parabolas in symmetric bioassays.
    Williams DA
    Biometrics; 1973 Dec; 29(4):695-700. PubMed ID: 4785234
    [No Abstract]   [Full Text] [Related]  

  • 27. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
    Abdel-Rahman SM; Kauffman RE
    Annu Rev Pharmacol Toxicol; 2004; 44():111-36. PubMed ID: 14744241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining the error of dose estimates and minimum and maximum acceptable concentrations from assays with nonlinear dose-response curves.
    Gottschalk PG; Dunn JR
    Comput Methods Programs Biomed; 2005 Dec; 80(3):204-15. PubMed ID: 16256244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of number of doses for maximum likelihood estimation of the ED50 for quantal dose-response data.
    Müller HG; Schmitt T
    Biometrics; 1990 Mar; 46(1):117-29. PubMed ID: 2350566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evolution of industrial toxicology toward vanishing doses and the human genome].
    Colombi A; Buratti M; Rubino FM; Giampiccolo R; Pulvirenti S; Brambilla G
    Med Lav; 2003; 94(1):69-82. PubMed ID: 12768958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A unifying concept for assessing toxicological interactions: changes in slope.
    Gennings C; Carter WH; Carchman RA; Teuschler LK; Simmons JE; Carney EW
    Toxicol Sci; 2005 Dec; 88(2):287-97. PubMed ID: 16081521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dose-response relationship: relevance for medical practice].
    Klinkhardt U; Harder S
    Med Klin (Munich); 2000 May; 95(1 Spec No):9-14. PubMed ID: 10851842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple test procedures for dose finding.
    Tamhane AC; Hochberg Y; Dunnett CW
    Biometrics; 1996 Mar; 52(1):21-37. PubMed ID: 8934584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormesis, adaptation, and the sandpile model.
    Stark M
    Crit Rev Toxicol; 2008; 38(7):641-4. PubMed ID: 18709573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.
    Dunne A; O'Hara T; Devane J
    Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-incidence relationships derived from superposition of distributions of individual susceptibility on mechanism-based dose responses for biological effects.
    Lutz WK; Lutz RW; Andersen ME
    Toxicol Sci; 2006 Mar; 90(1):33-8. PubMed ID: 16237192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability and pharmacokinetic analysis of drug responding systems.
    Smolen VF
    Annu Rev Pharmacol Toxicol; 1978; 18():495-522. PubMed ID: 348066
    [No Abstract]   [Full Text] [Related]  

  • 39. Parallel dose-response curves in combination experiments.
    Sühnel J
    Bull Math Biol; 1998 Mar; 60(2):197-213. PubMed ID: 9559575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An alternative approach to the optimal design of an LD50 bioassay.
    Markus RA; Frank J; Groshen S; Azen SP
    Stat Med; 1995 Apr; 14(8):841-52. PubMed ID: 7644863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.